Target intelligence / Profile preview

Type III secretion system needle tip protein PcrV (PcrV)

Target
PcrV
Molecular classification
Bacterial protein, Virulence factor, Type III secretion system needle tip protein
01

Overview

The Type III secretion system needle tip protein PcrV is a critical virulence factor found in Pseudomonas aeruginosa, an opportunistic pathogen frequently associated with healthcare-related infections. PcrV is localized at the distal tip of the bacterial Type III secretion system (T3SS) needle, where it acts as a scaffold for the assembly of the translocon pore, composed of the proteins PopB and PopD, within the host cell membrane (UniProt: P72170). This structural assembly is essential for the direct translocation of potent effector toxins, such as ExoS and ExoU, into the host cytoplasm, leading to cellular damage and evasion of the host immune system (Sawa et al., 1999). Due to its external location and high level of conservation across clinical strains, PcrV is a prominent target for passive immunization strategies using monoclonal antibodies. Therapeutic candidates like Gremubamab and KB001-A aim to neutralize PcrV, thereby preventing toxin delivery and attenuating the severity of pneumonia and other invasive P. aeruginosa infections (ClinicalTrials.gov: NCT02696031). This anti-virulence approach provides a potential alternative or adjunct to traditional antibiotics by disarming the pathogen without directly inducing bactericidal selective pressure.

Other names
PcrVType III secretion protein PcrVV-antigen homologLow calcium response protein VPseudomonas aeruginosa PcrV
02

Mechanism of action

Binding to the PcrV protein at the apex of the T3SS needle prevents the assembly of the translocon pore (PopB/PopD) in the host cell membrane, thereby blocking the injection of cytotoxic effector proteins into host cells (Sawa et al., 1999; DiGiandomenico et al., 2014).

03

Biological functions

Type III secretion system (T3SS) assemblyTranslocon pore formationToxin delivery regulationHost cell membrane penetrationBacterial pathogenesis
04

Disease associations

Pseudomonas aeruginosa infectionVentilator-associated pneumoniaCystic fibrosis exacerbationSepsisHospital-acquired pneumonia
05

Safety considerations

Immunogenicity of monoclonal antibodiesTarget limited to T3SS-expressing strainsPotential for strain-specific variations in PcrV sequenceChallenges in achieving sufficient therapeutic levels in the lung (epithelial lining fluid)
06

Interacting drugs

Gremubamab (MEDI3902)

2 more in the full profile.

07

Biomarkers

Pseudomonas aeruginosa T3SS genotypeExoU and ExoS effector protein levelsPcrV expression in clinical isolates

Beyond the preview

Go deeper on Type III secretion system needle tip protein PcrV (PcrV).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Type III secretion system needle tip protein PcrV (PcrV).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call